Literature DB >> 8297716

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

M Kusaka1, K Sudo, E Matsutani, Y Kozai, S Marui, T Fujita, D Ingber, J Folkman.   

Abstract

Recently, we reported the anti-angiogenic action along with anti-tumour activity of TNP-470 (AGM-1470). In this study, the effect of TNP-470 on the growth of human umbilical vein endothelial (HUVE) cells was examined. TNP-470 inhibited the growth of HUVE cells in a biphasic manner. The inhibition was cytostatic in the first phase (complete inhibition at 300 pg ml-1 to 3 micrograms ml-1 with an IC50 of 15 pg ml-1) and cytotoxic in the second phase (> or = 30 micrograms ml-1). The cytostatic inhibition of HUVE cell growth by TNP-470 was durable after washing out TNP-470 in culture. Incorporation of thymidine but not uridine and leucine by HUVE cells was inhibited in the first phase, while that of all three compounds was inhibited in the second phase. Human and rat endothelial cells among various types of cells were the most sensitive to the cytostatic inhibition, while differences in the cytotoxic inhibition were minimal. These results suggest that TNP-470 exerts its specific anti-angiogenic action by inhibiting cytostatically growth of endothelial cells in a relatively specific manner.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8297716      PMCID: PMC1968693          DOI: 10.1038/bjc.1994.41

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

2.  Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.

Authors:  M Kusaka; K Sudo; T Fujita; S Marui; F Itoh; D Ingber; J Folkman
Journal:  Biochem Biophys Res Commun       Date:  1991-02-14       Impact factor: 3.575

Review 3.  Regulators of angiogenesis.

Authors:  M Klagsbrun; P A D'Amore
Journal:  Annu Rev Physiol       Date:  1991       Impact factor: 19.318

Review 4.  Novel growth regulatory factors and tumour angiogenesis.

Authors:  R Bicknell; A L Harris
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

Review 6.  Tumor angiogenesis.

Authors:  J Folkman
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

7.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

Review 8.  Development of angiogenesis inhibitors for clinical applications.

Authors:  T E Maione; R J Sharpe
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

9.  Chemical modification of fumagillin. I. 6-O-acyl, 6-O-sulfonyl, 6-O-alkyl, and 6-O-(N-substituted-carbamoyl)fumagillols.

Authors:  S Marui; F Itoh; Y Kozai; K Sudo; S Kishimoto
Journal:  Chem Pharm Bull (Tokyo)       Date:  1992-01       Impact factor: 1.645

10.  Angiogenesis inhibition suppresses collagen arthritis.

Authors:  D J Peacock; M L Banquerigo; E Brahn
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more
  56 in total

Review 1.  Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors.

Authors:  H Malonne; I Langer; R Kiss; G Atassi
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

Review 2.  The role of angiogenesis in rheumatoid arthritis: recent developments.

Authors:  A E Koch
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

3.  The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

Authors:  J R Yeh; R Mohan; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

Review 4.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

5.  Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) Inhibits Tumor Angiogenesis, Growth and Spontaneous Metastasis of MKL-4 Human Breast Cancer Cells in Female Athymic Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1994-12-30       Impact factor: 4.239

6.  Inhibitory Effect of the Angiogenesis Inhibitor O-(Chloroacetyl-carbamoyl)fumagillol(TNP-470) on Tumor Growth and Metastasis of Murine Mammary Tumor Cell Line (JYG-B)Inoculated in Female Nude Mice.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

7.  Binding of alpha-hydroxy-beta-amino acid inhibitors to methionine aminopeptidase. The performance of two types of scoring functions.

Authors:  Anne Techau Jørgensen; Morten Dahl Sørensen; Fredrik Björkling; Tommy Liljefors
Journal:  J Comput Aided Mol Des       Date:  2003 May-Jun       Impact factor: 3.686

8.  Antitumor effect of TNP-470 is not associated to decrease of angiogenesis in an experimental malignant neuroectodermic tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

9.  A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines.

Authors:  A Mukherjee; K Huber; H Evans; N Lakhani; S Martin
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

10.  Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.

Authors:  S Yanai; H Okada; K Saito; Y Kuge; M Misaki; Y Ogawa; H Toguchi
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.